Collaboration and License Agreement - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2021	Jan. 01, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized	$ 33,971,000	$ 2,702,000
ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized	26,900
Novartis | Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized	30,800,000	2,300,000
Deferred revenue	0	30,200,000	$ 30,200,000	$ 800,000
Novartis | Collaborative Arrangement | Further obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue	0
Novartis | Collaborative Arrangement | Reimbursable Research and Development Costs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable	$ 0	$ 400,000